FindTrial
Sign In

Gefitinib 250 mg

DRUG3 trials

Sponsors

AstraZeneca, Allist Pharmaceuticals, Inc., Yuhan Corporation

Conditions

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung CancerLocally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung CancerNon-Small Cell Lung Cancer

Phase 3

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
CompletedNCT02296125
AstraZenecaLocally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
Start: 2014-12-03End: 2025-11-20Updated: 2026-04-21
Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）
Active, not recruitingNCT03787992
Allist Pharmaceuticals, Inc.Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
Start: 2019-05-30End: 2026-03-31Updated: 2025-04-11
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
CompletedNCT04248829
Yuhan CorporationNon-Small Cell Lung Cancer
Start: 2020-02-13End: 2026-04-22Updated: 2026-06-29

Related Papers

Neoadjuvant lazertinib with or without chemotherapy for patients with epidermal growth factor receptor ( <i>EGFR</i> )-mutated resectable non-small cell lung cancer (NSCLC): NeoLazer trial.
Journal of Clinical Oncology2025-05-28
Abstract 1944: Longitudinal circulating tumor DNA (ctDNA) analysis and acquired mechanisms of resistance to osimertinib (osi) in the China cohort of the FLAURA study
Cancer Research2025-04-21
EGFR mutation testing across the osimertinib clinical program.
2025-04-182 citations
Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study
BMC Medicine2024-10-087 citations
Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3.
2024-07-1711 citations
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non−Small Cell Lung Cancer
JAMA Oncology2024-06-1350 citations
A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice
Cancers2024-03-0716 citations
28P Long-term survival and treatment (tx) patterns in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced NSCLC treated with first-line (1L) osimertinib (osi): German cohort of a global real-world (rw) observational study
ESMO Open2024-03-011 citations
Protein Kinase Inhibitors Indicated for Lung Cancer: Pharmacodynamics, Pharmacokinetics, Adverse Drug Reactions, and Evaluation in Clinical Trials
Journal of Clinical Pharmacy and Therapeutics2024-01-013 citations
Longitudinal Circulating Tumor <scp>DNA</scp> Modeling to Predict Disease Progression in First‐Line Mutant Epidermal Growth Factor Receptor <scp>Non‐Small</scp> Cell Lung Cancer
Clinical Pharmacology & Therapeutics2023-11-289 citations
Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic.
2023-11-183 citations
LASER301 Study Unveils Insights of CNS Metastases in NSCLC
Oncology Times2023-11-06
Real-World Data From First-Line EGFRm NSCLC Treatment
Oncology Times2023-11-06
Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis.
2023-10-2224 citations
Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
Clinical Cancer Research2023-06-2855 citations
Patient-reported outcomes of furmonertinib versus gefitinib in patients with locally advanced or metastatic, <i>EGFR</i> mutation-positive non-small cell lung cancer (FURLONG): A multicenter, double-blind, randomized phase 3 study.
Journal of Clinical Oncology2023-06-01
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
Nature Communications2023-02-27209 citations
Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer.
2023-02-227 citations
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer
Journal of Clinical Oncology2022-10-2696 citations
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study.
2022-06-02178 citations

22 more papers not shown